期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血浆溶血磷脂酸水平的测定在卵巢癌患者诊断中的价值 被引量：6

原文传递
导出
摘要 CAl25是目前临床上用于检测卵巢癌较常用f生物学指标．但敏感性和特异性较低[1]．且对早期诊断价值不高{2,3}。近年来研究发现．溶血磷脂（lysophosphatidic acid，LPA）可作为卵巢癌及其他!科恶性肿瘤的标志物，可刺激卵巢癌细胞的生长、浸润和转移。我们自2010年lO月至2012年4月通过对卵巢癌患者血浆LPA水平的测定．并与血；CAl25检测结果进行比较．探讨血浆LPA水平在卵巢癌患者诊断中的价值．报告如下。
作者 满志然 王永志
机构地区 北京市第六医院检验科
出处 《北京医学》 CAS 2014年第1期63-64,共2页 Beijing Medical Journal
关键词 血浆溶血磷脂酸 早期诊断价值 卵巢癌患者 测定 水 检测结果 生物学指标 卵巢癌细胞
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Bese T,Barbaros M,BaykarRa E. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer[J].J Gynecol Oncol,2010.248-254.
  • 2Sedláková I,Vávrová J,To(s)ner J. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer[J].{H}TUMOUR BIOLOGY,2011.311-316.
  • 3Dutta S,Wang FQ,Fishman DA. The dire need to develop a clinically validated screening method for the detection of early-stageovarian cancer[J].Biomark Med,2010.437-439.
  • 4Pua TL,Wang FQ,Fishman DA. Roles of LPA in ovarian cancer development and progression[J].{H}FUTURE ONCOLOGY,2009.1659-1673.
  • 5Tanyi J,Rigó J Jr.Orv Hetil. Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelialovarian cancers[J].2009.1109-1118.
  • 6Pozlep B,Meleh M,Kobal B. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors[J].{H}European Journal of gynaecological oncology,2007.394-399.
  • 7Meleh M,Pozlep B,Mlakar A. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer[J].{H}Journal of Chromatography B:Analytical Technologies in the Biomedical and Life Sciences,2007.287-291.
  • 8Sedlákova I,Vávrová J,Tosner J. Lysophosphatidic acid in ovarian cancer patients[J].{H}Ceska Gynekologie,2006.312-317.
  • 9梁宏峰,张浩,马秀岩.溶血磷脂酸及CA125在卵巢癌诊断中的价值对比分析[J].中国综合临床,2011,27(4):348-350. 被引量：6
  • 10徐文生,徐红.溶血磷脂酸与卵巢癌的关系研究进展[J].广西医学,2011,33(7):879-881. 被引量：2

二级参考文献22

  • 1段满乐,武凡.磷脂酶A_2和溶血磷脂酸在卵巢癌诊断中的价值[J].中华检验医学杂志,2005,28(6):622-624. 被引量：12
  • 2李留霞,张建好,乔玉环,王淼,周蔚.卵巢上皮性肿瘤患者血浆溶血磷脂酸水平测定[J].郑州大学学报（医学版）,2007,42(2):226-228. 被引量：10
  • 3Ren J,Xiao YJ,Singh LS,et al.Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion,migration,and invasion of ovarian cancer cells[J].Cancer Res,2006,66(6):3006-3014.
  • 4Sutphen R,Xu Y,Wilbanks GD,et al.Lysophospholipids are potential biomarkers of ovarian cancer[J].Cancer Epidemiol Biomarkers Prev,2004,13 (7):1185-1191.
  • 5Xu Y,Shen Z,Wiper DW,et al.Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers[].The Journal of The American Medical Association.1998
  • 6Fujita T,Miyamoto S,Onoyama I,et al.Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer[].Cancer Letters.2003
  • 7Furui T,LaPushin R,Mao M,et al.Overexpression of Edg2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner[].Clinical Cancer Research.1999
  • 8Sawada K,Morishige K I,Tahara M,et al.Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho[].Cancer Research.2002
  • 9Tanyi JL,Morris AJ,Wolf JK,et al.The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer[].Cancer Research.2003
  • 10Hu Y L,Albanese C,Pestell R G,et al.Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells[].Journal of the National Cancer Institute.2003

共引文献8

同被引文献47

  • 1于占彩,李振光,伍期专.溶血磷脂类分子与卵巢癌[J].中国实用医刊,2010,37(21):60-62. 被引量：1
  • 2Lori E W , John R L , Diljeet K S , et al. Survival a n d reproductive outco m e s in w o m e n treated for malignant ovarian g e r m cell tumors[J]. G y necologicO n c o l o g y , 2 0 1 1 , 1 2 1 ( 2 ) :2 8 5 - 2 8 9 .
  • 3S c h u m m e r M , Drescher C , Forrest R , et al. Evaluation of ovarian cancerremission markers H E 4 , M M P 7 an d Mesothelin by comparison to theestablished marker C A 1 2 5 [J] . Gynecol Oncol ,2012,125 (1) :65 - 6 9 .
  • 4Z h o n g J , K a n g J , W a n g X , et al. T A T - O S B P - 1 - M K K 6 ( E ) , a n o -vel T A T - fusion protein with high selectivity for h u m a n ovarian cancer,exhibits anti - tumor activity[J] . M e d O n c o l , 2 0 1 5 , 3 2 ( 4 ) :4 9 5 - 4 9 6 .
  • 5Z h o u B , S h u B , X i T , et al. D u b 3 expression correlates with t u m o r progressiona n d poor prognosis in h u m a n epithelial ovarian cancer[J]. Biom e d Pha r m a c o t h e r , 2 0 1 5 ,70 :8 4 - 89.
  • 6Y a o D , Lin Z , W u J. N e a r - Infrared Fluorogenic Probes with Polarity -Sensitive Emission for in Vivo Imaging of an Ovarian Cancer Biomarker[J], A C S A p p l Mater Interfaces, 2 0 1 6 , 8 ( 9 ) :5 8 4 7 - 5 8 5 6 .
  • 7孙维荣,才红霞,王赫.CA125在卵巢癌诊断与治疗中的应用[J].吉林医学,2010,31(14):2007-2008. 被引量：10
  • 8张建好,韩延敏.卵巢上皮性癌患者血浆溶血磷脂酸测定[J].郑州大学学报（医学版）,2010,45(5):867-868. 被引量：2
  • 9林碧君,李波,李春仙.HE4和CA125联检在卵巢癌中的应用价值[J].放射免疫学杂志,2010,23(5):564-565. 被引量：9
  • 10李强,王伟,王强修,连岩,孟燕.LPA、CA125与经阴道彩色多普勒超声联合诊断卵巢上皮癌的临床价值[J].现代妇产科进展,2010,19(11):832-834. 被引量：6

引证文献6

二级引证文献48

北京医学
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部